Introduction
In patients with advanced and recurrent estrogen receptor (ER)-positive breast cancer, endocrine therapy is less toxic than cytotoxic agents and thus contributes to qual-ity of life. Fulvestrant is a pure anti-estrogen with no agonistic actions, which blocks dimerization of the estrogen-ER complex and down-regulates the ER. At a dose of 250 mg, fulvestrant is at least as effective as anas- In the phase III CONFIRM trial, which compared doses of fulvestrant (250 mg every 28 days vs 500 mg, on days 0, 14, 28, and every 28 days thereafter) in postmenopausal women with ER-positive, locally advanced or metastatic breast cancer for disease relapse, or disease progression after treatment with an aromatase inhibitor, fulvestrant 500 mg was associated with statistically significant increases in progression free and overall survival and was not associated with greater toxicity than fulvestrant 250 mg 3, 4 . Fulvestrant 500 mg has been an option for endocrine therapy for advanced or recurrent breast can- This study aimed to clarify the effectiveness and safety of fulvestrant 500 mg in clinical settings. We also focused on post-fulvestrant therapy.
Materials and Methods
This was a multicenter, both prospective and retrospec- The effectiveness of subsequent post-fulvestrant therapy was also evaluated using the modified RECIST, according to the primary physician's judgment.
Statistical Analyses
Statistical analyses were performed with JMP version 10 (SAS Institute, Cary, NC, USA). TTF and OS distributions were estimated according to the Kaplan-Meier method. 
Results

Patient Population
Efficacy
Median TTF was 6.1 months (95% CI: 5.1 7.7) ( Fig. 1) and median OS was 28.5 months (95% CI: 18.7 34.4) ( Fig.   2) . At the data collection cut-off date of April 30, 2015, 46.2% of patients (61/132) had died.
Best overall response is shown in Table 3 .
The ORR was 12.9%, including CR in 2.3% and PR in 10.6% of patients. The rate of long stable disease, i.e. SD for more than 24 weeks, was 32.6%. The CBR was 45.5%. 
Furthermore, fulvestrant was also active in subgroups of
Safety
AEs are shown in Table 4 . The total number of AEs was 48 (36.4%). All of the AEs that developed during fulvestrant treatment had rates below 10%. The most common AE was injection site reaction, which occurred in 12 patients (9.1%). Grade 3 AEs developed in 3 patients (2.3%), one each with nausea, a duodenal ulcer, and cellulitis. There were no Grade 4 AEs in our study participants.
Selection of Post-Fulvestrant Therapy and Efficacy
The numbers of patients given subsequent therapy after fulvestrant, were 54 (55.7%), 42 (43.3%), and 1 (1%) receiving chemotherapy, non-fulvestrant endocrine therapy, and mTOR inhibitor (exemestane+mTORi), respec-tively. As to subsequent therapy after fulvestrant, the response to chemotherapy was higher than that to endocrine therapy ( Table 5 ).
The TTF of subsequent therapy with chemo+mTORi was significantly longer than that obtained with subsequent endocrine therapy after fulvestrant, i.e. 6.2 versus 2.8 months, respectively (HR=0.46; 95% CI, 0.293 0.728; P =0.0019) ( Fig. 3) .
Discussion
Fulvestrant is an option for treating hormone receptor positive, postmenopausal metastatic, and advanced breast cancer in patients and can be administered during any line of therapy. In this study, eligible patients were postmenopausal woman with locally advanced or metastatic ER-positive breast cancer who received treatment with fulvestrant. All patients were given endocrine therapies prior to fulvestrant administration. Fluvestrant was given as the third or later line of endocrine therapy to 70% of patients.
In our dataset, the median TTF for fulvestrant 500 mg was 6.1 months and median OS was 28.5 months.
In the CONFIRM study, which compared fulvestrant 500 mg to fulvestrant 250 mg for treatment of postmenopausal women with ER-positive advanced breast cancer who experienced progression after prior endocrine therapy, median progression free survival with fulvestrant 500 mg was 6.5 months 3 and median OS was 26.4 Several cohort studies focusing on fulvestrant have been reported both in Japan and abroad 8, 9 . In a cohort study As to subsequent therapy after fulvestrant, the response to chemotherapy was significantly higher than that to endocrine therapy. In this study, all patients received at least two endocrine therapies after fulvestrant.
More than 70% of patients had previously received three endocrine therapies. Since hormone receptor sensitivity diminishes, endocrine therapy does not yield good responsiveness in the long term.
Molecularly-targeted therapies with mTORi are rarely used as subsequent therapy after fulvestrant. One of the reasons for this drug not being administered, might be that it had only been available for a short period when this study was being conducted. In a recent randomized inhibitor added to fulvestrant. However, in cases in which the duration of previous endocrine therapy is long and there is no liver metastasis, it may be an option to start treatment with fulvestrant alone 8 .
In conclusion, our study showed fulvestrant 500 mg to be an effective and well-tolerated treatment for postmenopausal women with metastatic breast cancer showing progression after endocrine therapies in actual clinical settings.
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